Rodin Therapeutics is discovering and developing first-in-class therapeutics that boost synaptic resilience to treat neurological and neuropsychiatric diseases. Its discovery strategy targets specific HDAC complexes and leverages novel chemical strategies to produce brain-penetrant small molecules. The company applies a unique translational approach to measure pro-synaptic effects in a clinical setting. Rodin’s programs are intended to address disorders that share impaired neuronal and synaptic function, including Alzheimer’s and Parkinson’s disease. The company completed a $27 million financing to advance its product candidates and accelerate programs toward clinical trials. Rodin also expanded its board as part of the financing, reflecting continued investor support for its development strategy. Rodin Therapeutics develops therapeutics for cognitive and other neurological disorders by applying epigenetics insights. The company has advanced an internal pipeline of epigenetic modulators and obtained an exclusive license to an additional chemical series discovered at the Broad Institute. Its drug candidates have potential to treat conditions including Parkinson’s disease, cognitive impairment in schizophrenia, and post-traumatic stress disorder. Rodin was co-founded in 2013 by Atlas Venture and Proteros Biostructures and is led by President and CEO Adam Rosenberg. The company entered a multi-year research collaboration with Biogen tied to its neuroscience epigenetics work. As part of its financing and collaboration activity, Rodin is positioning to advance its preclinical pipeline toward clinical development. Rodin Therapeutics discovers and develops first-in-class therapeutics for cognitive and CNS disorders by targeting epigenetic mechanisms and using structural biology capabilities. The company leverages a strategic partnership with Proteros for structure-accelerated lead discovery and has an exclusive license to an additional chemical series developed at the Broad Institute. Rodin has assembled a Scientific Advisory Board chaired by Li-Huei Tsai and staffed by academic and industry experts. The leadership team includes Bruce Booth (Chairman and acting CEO), Marty Jefson (CSO), Ankit Mahadevia (Acting CBO), and Barbara Tate (Head of Biology). Rodin plans to use its recent financing to advance its pipeline of selective epigenetic modulators toward the clinic.

Total raised

$57M

Funding rounds

3

Latest round

Equity

Latest activity

Sep 2017